Yes, cardiolipin antibody and anticardiolipin antibody are the same thing—these terms are used interchangeably in medical practice.
Terminology Clarification
The terms "cardiolipin antibody," "anticardiolipin antibody," and "anti-cardiolipin antibody" (abbreviated as aCL) all refer to the identical autoantibody. This is consistently demonstrated throughout current medical literature and guidelines 1, 2.
Context in Clinical Practice
These antibodies are one of three laboratory criteria used to diagnose antiphospholipid syndrome (APS), alongside:
- Lupus anticoagulant (LA)
- Anti-beta2-glycoprotein I antibodies (aβ2GPI)
The most recent 2025 ISTH guidance uses "anti-cardiolipin antibodies (aCL)" as the standard nomenclature 1, while the 2018 ISTH criteria similarly refer to "anticardiolipin antibodies (aCL)" 2. Both formulations describe the same antibody.
Important Clinical Distinction
What matters clinically is not the naming convention, but rather understanding that:
- aCL assays detect β2GPI-dependent antibodies when cardiolipin is immobilized on a solid phase in the presence of β2-glycoprotein I 1
- These are distinct from anti-β2GPI antibodies, though there is significant overlap between the two tests 1
- Both IgG and IgM isotypes should be measured using ELISA or automated systems 1, 2
- Results above the 99th percentile of normal controls are considered positive 2
- The 2023 ACR/EULAR criteria define moderate positivity as ≥40 Units and high positivity as ≥80 Units 1
Common Pitfall
Do not confuse the terminology variation with actual antibody differences—whether a laboratory report states "cardiolipin antibody" or "anticardiolipin antibody," they are measuring the same entity and should be interpreted identically according to established thresholds.